GlassScriptPhysician profile
Mariananda P Kumar
NPI 1316049679
$2,235.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $743 · 2021: $77.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $514.74 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $405.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.43 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $180.63 | 2019-2020 | |
| Novo Nordisk INC | $145.61 | 2019-2020 | |
| Glaxosmithkline, LLC. | $126.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $102.23 | 2019-2020 | |
| Dexcom, INC. | $77.00 | 2021 | |
| Amarin Pharma, INC. | $76.91 | 2019-2020 | |
| Medtronic Vascular, INC. | $73.81 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $60.94 | 2019 | |
| Lilly USA, LLC | $58.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.36 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.78 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariananda Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.